KRM-III

KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC50 of ~5 μM. Anti-inflammatory activity[1].

Product Specifications

CAS Number

[79220-94-3]

UNSPSC

12352005

Hazard Statement

H319

Target

Nuclear Factor of activated T Cells (NFAT)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/krm-iii.html

Concentration

10mM

Purity

98.08

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

S=C1NC(C2=CC=CC=C2)=CN1C3=CC=CC=C3

Molecular Formula

C15H12N2S

Molecular Weight

252.33

Precautions

H319

References & Citations

[1]Eun Joo Jung, et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J Pharmacol Exp Ther. 2009 Dec;331 (3) :1005-13.